Ontology highlight
ABSTRACT: Importance
The US Food and Drug Administration recognizes total abstinence and no heavy drinking days as outcomes for pivotal pharmacotherapy trials for alcohol use disorder (AUD). Many patients have difficulty achieving these outcomes, which can discourage seeking treatment and has slowed the development of medications that affect alcohol use.Objective
To compare 2 drinking-reduction outcomes with total abstinence and no heavy drinking outcomes.Design, setting, and participants
Data were obtained from 3 multisite, randomized, placebo-controlled clinical trials of medications for treating alcohol dependence (naltrexone, varenicline, and topiramate) in adults with DSM-IV-categorized alcohol dependence.Main outcomes and measures
Within each trial, the percenta
SUBMITTER: Falk DE
PROVIDER: S-EPMC6450273 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature